Therapeutic Targets in Alveolar Rhabdomyosarcoma

描述（由申请人提供）：实体瘤的进展和转移是癌症患者死亡的主要原因。儿童肌肉癌腺泡状横纹肌肉瘤就是一个典型的例子。对疾病特异性进展机制的理解存在差距，这是晚期腺泡状横纹肌肉瘤患者预后不佳的原因。我们在一项国家临床试验中对横纹肌肉瘤患者基因表达的初步研究表明，血小板源性生长因子受体A（PDGFR-A）可能是疾病进展和转移的介导者。在我们的研究中，PDGFR-A被发现是Pax 3：Fkhr的转录靶点，Pax 3：Fkhr是在大多数肺泡型横纹肌肉瘤中发现的易位介导的融合基因。我们推测配体依赖性或组成性PDGFR-A信号通路在腺泡型横纹肌肉瘤的进展和转移中起重要作用。为了检验这一假设，我们已经产生了条件性小鼠肿瘤模型，其真实地再现了人类肺泡型横纹肌肉瘤的原发突变和转移进展。该模型中的肿瘤对受体酪氨酸激酶抑制剂伊马替尼（Imatinib）有显著的反应，伊马替尼显著抑制PDGFR-A信号传导。我们的第一个目的是通过体外功能测试来描述横纹肌肉瘤中PDGFR-A信号通路。对于这些实验，将在存在或不存在PDGFR-A抑制剂或siRNA的情况下检查小鼠和人腺泡状横纹肌肉瘤细胞培养物中Akt、MAPK和PKC信号传导途径的改变。将在卵内测定在PDGFR-A抑制条件下转移的功能能力。我们的第二个目的是确定PDGFR-A阻断对横纹肌肉瘤的病理生理影响。为了实现这一目标，我们将使用PDGFR-A的条件等位基因来消除我们的肺泡横纹肌肉瘤小鼠模型中的PDGFR-A信号传导，并且我们将测量有和没有PDGFR-A信号传导的发作、频率和进展的差异。本研究为儿童腺泡状横纹肌肉瘤和其他肿瘤的分子治疗建立了系统的、合理的遗传学方法的原理证明。 公共卫生相关性：实体瘤的进展和转移是癌症患者死亡的主要原因。儿童肌肉癌腺泡状横纹肌肉瘤就是一个典型的例子。对疾病特异性进展机制的理解存在差距，这是晚期腺泡状横纹肌肉瘤患者预后不佳的原因。本研究血小板衍生生长因子在癌症进展中的作用，为儿童腺泡状横纹肌肉瘤和其他肿瘤的分子治疗建立了系统的、合理的遗传学方法的主要证据。

DESCRIPTION (provided by applicant): Progression and metastasis of solid tumors is a principal cause of death for cancer patients. The childhood muscle cancer alveolar rhabdomyosarcoma is a classic example. A gap in understanding the disease-specific mechanisms of progression underlies the dismal outcome for patients with advanced alveolar rhabdomyosarcoma. Our initial studies of rhabdomyosarcoma gene expression amongst patients enrolled in a national clinical trial suggest that the platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis. In our studies PDGFR-A has been found to be a transcriptional target of Pax3:Fkhr, the translocation-mediated fusion gene found in the majority of alveolar rhabdomyosarcomas. We hypothesize that ligand-dependent or constitutive PDGFR-A signaling pathways play a prominent role in progression and metastasis of alveolar rhabdomyosarcoma. To test this hypothesis, we have generated conditional mouse tumor models that authentically recapitulate the primary mutations and the metastatic progression of alveolar rhabdomyosarcomas in humans. Tumors in this model have dramatic responses to the receptor tyrosine kinase inhibitor, Imatinib, which significantly inhibits PDGFR-A signaling. Our first aim is to delineate the PDGFR-A signaling pathway in rhabdomyosarcoma by functional testing in vitro. For these experiments, mouse and human alveolar rhabdomyosarcoma cell cultures will be examined for alterations of the Akt, MAPK, and PKC signaling pathways in the presence or absence of PDGFR-A inhibitors or siRNA. The functional ability to metastasize under PDGFR-A inhibitory conditions will be assayed in ovo. Our second aim is to determine the pathophysiological impact of PDGFR-A blockade for rhabdomyosarcoma in vivo. To achieve this aim, we will use a conditional allele of PDGFR-A to abrogate PDGFR-A signaling in our mouse model of alveolar rhabdomyosarcoma, and we will measure the differences in onset, frequency, and progression with and without PDGFR-A signaling. This study establishes proof-of-principal for a systematic, rational genetic approach to molecular therapeutics in childhood alveolar rhabdomyosarcomas and other tumors. PUBLIC HEALTH RELEVANCE: Progression and metastasis of solid tumors is a principal cause of death for cancer patients. The childhood muscle cancer alveolar rhabdomyosarcoma is a classic example. A gap in understanding the disease-specific mechanisms of progression underlies the dismal outcome for patients with advanced alveolar rhabdomyosarcoma. This study of platelet-derived growth factors in cancer progression establishes proof-of- principal for a systematic, rational genetic approach to molecular therapeutics in childhood alveolar rhabdomyosarcomas and other tumors.